ZA200201161B - Methods of treating nuclear factor-kappa B mediated diseases and disorders. - Google Patents

Methods of treating nuclear factor-kappa B mediated diseases and disorders.

Info

Publication number: ZA200201161B
Authority: ZA; South Africa
Prior art keywords: kappa; disorders; methods; mediated diseases; nuclear factor
Prior art date: 2001-02-12

Application number

ZA200201161A

Other languages

English (en)

Inventor

Joseph Anthony Cornicelli

Sotirios Konstant Karathanasis

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-12

Filing date

2002-02-11

Publication date

2003-08-11

2002-02-11 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2003-08-11 Publication of ZA200201161B publication Critical patent/ZA200201161B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Cardiology (AREA)
Hematology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200201161A 2001-02-12 2002-02-11 Methods of treating nuclear factor-kappa B mediated diseases and disorders. ZA200201161B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26820301P	2001-02-12	2001-02-12

Publications (1)

Publication Number	Publication Date
ZA200201161B true ZA200201161B (en)	2003-08-11

Family

ID=23021923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201161A ZA200201161B (en)	2001-02-12	2002-02-11	Methods of treating nuclear factor-kappa B mediated diseases and disorders.

Country Status (11)

Country	Link
US (1)	US20020183384A1 (xx)
EP (1)	EP1236468A1 (xx)
JP (1)	JP2002275062A (xx)
KR (1)	KR20020067011A (xx)
CN (1)	CN1370526A (xx)
AU (1)	AU1539402A (xx)
CA (1)	CA2369967A1 (xx)
HU (1)	HUP0200493A3 (xx)
IL (1)	IL148034A0 (xx)
NZ (1)	NZ517021A (xx)
ZA (1)	ZA200201161B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR037097A1 (es)	2001-10-05	2004-10-20	Novartis Ag	Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
GB0325192D0 (en) *	2003-10-29	2003-12-03	Astrazeneca Ab	Method of use
WO2005099686A1 (ja) *	2004-04-07	2005-10-27	Fujicco Co., Ltd.	カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物
KR20070087096A (ko)	2004-12-14	2007-08-27	아스트라제네카 아베	Ｄｇａｔ 억제제로서의 옥사디아졸 유도체
CA2608214C (en)	2005-05-19	2013-08-20	Merck Frosst Canada Ltd.	Quinoline derivatives as ep4 antagonists
EP1966221A1 (en)	2005-12-22	2008-09-10	AstraZeneca AB	Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors
ES2356097T3 (es)	2006-05-30	2011-04-04	Astrazeneca Ab	Ácidos 5-fenilamino-1,3,4-oxadiazol-2-ilcarbonilamino-4-fenoxi-ciclohexancarboxílico sustituidos como inhibidores de la acetil coenzima a diacilglicerol aciltransferasa.
CA2651663A1 (en)	2006-05-30	2007-12-06	Astrazeneca Ab	Chemical compounds
AU2007255180B2 (en) *	2006-06-08	2011-02-03	Astrazeneca Ab	Benzimidazoles and their use for the treatment of diabetes
KR100842351B1 (ko) *	2007-01-04	2008-06-30	한국생명공학연구원	인돌 유도체를 유효성분으로 함유하는 암 예방 및 치료용약학적 조성물
BRPI0815490A2 (pt) *	2007-08-17	2017-03-21	Astrazeneca Ab	composto, composição faramcêutica, método para tratar diabetes mellitus e/ou obesidade em um animal de sangue quente, e, processo para preparar um composto
AU2008339570B2 (en)	2007-12-20	2012-04-12	Astrazeneca Ab	Carbamoyl compounds as DGAT1 inhibitors 190
BRPI0924669A2 (pt) *	2008-12-19	2016-01-26	Astrazeneca Ab	composto, uso de um composto, método para tratar a diabete melito e/ou obesidade, e, composição farmacêutica
US9339524B2 (en)	2009-03-11	2016-05-17	Jellice Co., Ltd.	Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food
TW201103895A (en)	2009-06-19	2011-02-01	Astrazeneca Ab	Chemical compounds
CN103040815B (zh) *	2011-10-13	2014-12-10	中国科学院上海药物研究所	一类2，4，6-三异丙基苯类化合物在制备治疗糖尿病的药物中的用途
JP6929792B2 (ja) *	2015-02-16	2021-09-01	ザユニバーシティオブクィーンズランド	スルホニル尿素及び関連化合物並びにその使用
CN107835688A (zh) *	2015-05-08	2018-03-23	得克萨斯州大学系统董事会	用于治疗阿尔茨海默病的神经元钙池操纵的钙进入途径的活化
KR20180133244A (ko)	2016-02-16	2018-12-13	더 유니버서티 어브 퀸슬랜드	설포닐유레아 및 관련 화합물 및 이의 용도
AU2017254523B2 (en) *	2016-04-18	2021-09-02	Novartis Ag	Compounds and compositions for treating conditions associated with NLRP activity
WO2019008029A1 (en)	2017-07-07	2019-01-10	Inflazome Limited	SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
CN110914256A (zh)	2017-07-07	2020-03-24	英夫拉索姆有限公司	新颖磺酰胺羧酰胺化合物
SG11201912166XA (en)	2017-07-24	2020-02-27	Novartis Inflammasome Research Inc	Compounds and compositions for treating conditions associated with nlrp activity
WO2019034693A1 (en)	2017-08-15	2019-02-21	Inflazome Limited	SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
WO2019034697A1 (en) *	2017-08-15	2019-02-21	Inflazome Limited	NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
EP3668842A1 (en) *	2017-08-15	2020-06-24	Inflazome Limited	Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN111107903A (zh)	2017-08-15	2020-05-05	英夫拉索姆有限公司	新颖的磺酰胺羧酰胺化合物
US20200361895A1 (en) *	2017-08-15	2020-11-19	Inflazome Limited	Novel sulfonamide carboxamide compounds
EP3668599A1 (en)	2017-08-15	2020-06-24	Inflazome Limited	Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
MX2020004423A (es) *	2017-11-09	2020-08-06	Inflazome Ltd	Nuevos compuestos de sulfonamida carboxamida.
US11834433B2 (en)	2018-03-02	2023-12-05	Inflazome Limited	Compounds
WO2019166628A1 (en)	2018-03-02	2019-09-06	Inflazome Limited	Novel compounds
WO2019166632A1 (en)	2018-03-02	2019-09-06	Inflazome Limited	Novel compounds
EP3759090A1 (en)	2018-03-02	2021-01-06	Inflazome Limited	Novel compounds
EP3759073A1 (en) *	2018-03-02	2021-01-06	Inflazome Limited	Sulfonamide derivates as nlrp3 inhibitors
US11905252B2 (en)	2018-03-02	2024-02-20	Inflazome Limited	Compounds
AU2019387370A1 (en)	2018-11-30	2021-06-10	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1449404A (en) *	1973-03-30	1976-09-15	Science Union & Cie	N-arylsulphonyl urea derivatives
US5194588A (en) *	1985-01-22	1993-03-16	Ici Americas Inc.	Aminoalcohol intermediates for peptide derivatives
US5245068A (en) *	1990-10-30	1993-09-14	Warner-Lambert Company	Oxysulfonyl carbamates
US5254715A (en) *	1990-11-07	1993-10-19	Warner-Lambert Company	Aminosulfonyl carbamates
US5214206A (en) *	1990-11-07	1993-05-25	Warner-Lambert Company	Aminosulfonyl urea acat inhibitors
US5198466A (en) *	1990-11-09	1993-03-30	Warner-Lambert Company	Oxysulfonyl urea acat inhibitors
US5254589A (en) *	1991-10-15	1993-10-19	Warner-Lambert Company	Sulfonyl urea and carbamate ACAT inhibitors
IL109431A (en) *	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
SK12598A3 (en) *	1995-08-04	1999-02-11	Warner Lambert Co	Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
GEP20001898B (en) *	1995-11-02	2000-01-05	Warner Lambert Co	Method and Pharmaceutical Composition for Regulating Lipid Concentration with Mam
US5948886A (en) *	1996-11-20	1999-09-07	Hoechst Marion Roussel, Inc.	Acylated enol derivatives of α-ketoesters and α-ketoamides
AU2738897A (en) *	1996-05-17	1997-12-09	Warner-Lambert Company	N-acyl sulfamic acid esters useful as hypocholesterolemic agents
KR100324058B1 (ko) *	1997-01-29	2002-02-16	디. 제이. 우드, 스피겔 알렌 제이	술포닐 우레아 유도체 및 인터루킨-1 활성 조절에서의 그의 용도
US6093744A (en) *	1997-04-21	2000-07-25	Warner-Lambert Company	N-acyl sulfamic acid esters useful as hypocholesterolemic agents
CO5200844A1 (es) *	1999-09-17	2002-09-27	Novartis Ag	Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP1145717B1 (en) *	2000-04-13	2004-05-12	Pfizer Products Inc.	Synergistic effect of glyburide and milrinone

2002
- 2002-02-01 CA CA002369967A patent/CA2369967A1/en not_active Abandoned
- 2002-02-04 AU AU15394/02A patent/AU1539402A/en not_active Abandoned
- 2002-02-04 NZ NZ517021A patent/NZ517021A/en unknown
- 2002-02-05 EP EP02002612A patent/EP1236468A1/en not_active Withdrawn
- 2002-02-06 IL IL14803402A patent/IL148034A0/xx unknown
- 2002-02-08 JP JP2002032755A patent/JP2002275062A/ja active Pending
- 2002-02-08 US US10/071,034 patent/US20020183384A1/en not_active Abandoned
- 2002-02-09 KR KR1020020007716A patent/KR20020067011A/ko not_active Application Discontinuation
- 2002-02-10 CN CN02104763A patent/CN1370526A/zh active Pending
- 2002-02-11 HU HU0200493A patent/HUP0200493A3/hu unknown
- 2002-02-11 ZA ZA200201161A patent/ZA200201161B/xx unknown

Also Published As

Publication number	Publication date
HUP0200493A3 (en)	2003-04-28
HU0200493D0 (en)	2002-04-29
KR20020067011A (ko)	2002-08-21
CA2369967A1 (en)	2002-08-12
CN1370526A (zh)	2002-09-25
IL148034A0 (en)	2002-09-12
US20020183384A1 (en)	2002-12-05
NZ517021A (en)	2003-09-26
AU1539402A (en)	2002-08-15
EP1236468A1 (en)	2002-09-04
HUP0200493A2 (en)	2002-10-28
JP2002275062A (ja)	2002-09-25

Publication	Publication Date	Title
ZA200201161B (en)	2003-08-11	Methods of treating nuclear factor-kappa B mediated diseases and disorders.
MXPA03007960A (es)	2003-12-04	Compuestos y metodos para el tratamiento de desordenes urogenitales.
MXPA03007816A (es)	2003-12-08	Calzoncillo desechable y metodo para proporcionar el mismo.
EP1455778A4 (en)	2007-09-12	METHODS OF TREATING PERIPHERAL NEUROVASCULAR MALAYS
GB2393202B (en)	2005-12-21	Methods of well treatment
AU2002332430A1 (en)	2003-02-17	Methods of treating neuropilin-mediated diseases
EP1416961A4 (en)	2005-12-14	COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
AU2001247331A1 (en)	2001-09-24	Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2002086502A8 (en)	2003-03-20	Methods for the diagnosis and treatment of bone disorders
HUP0401808A3 (en)	2005-11-28	Dosage forms, devices and methods of treatment
HK1041880A1 (en)	2002-07-26	Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
MXPA03006817A (es)	2003-11-13	Metodo de tratamiento de enfermedades inflamatorias e inmunes usando inhibidores de la ikb cinasa (ikk).
EP1416957A4 (en)	2006-08-02	TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES
EP1442062A4 (en)	2005-11-09	METHOD FOR TREATING CARCINOMA
MXPA03008582A (es)	2003-12-08	Agentes y metodos para tratamiento de cancer.
AU5754701A (en)	2002-01-30	Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
MXPA03003741A (es)	2003-07-28	Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
IL137429A0 (en)	2001-07-24	Methods and compsitions for treating diseases and conditions of the eye
EP1379236A4 (en)	2009-01-21	TREATMENT OF TICS, TREMORS AND RELATED DISORDERS
GB0004531D0 (en)	2000-04-19	The treatment of respiratory diseases
AU2002220266A1 (en)	2002-05-21	Methods for the identification and the treatment of cardiovascular disease
GB2389532C (en)	2005-09-08	The method of treating cancer
ZA200205098B (en)	2004-03-31	Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
MXPA03004190A (es)	2003-09-22	Tratamiento de trastornos de ansiedad.
AU2001249262A1 (en)	2001-10-03	Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof